Spirox, Inc., a Menlo Park, CA-based medical device company, closed a $45m Series C round of financing.
The round was led by KKR, with participation from new investor HealthQuest Capital and existing shareholders Aisling Capital, Aperture Venture Partners and Venrock. As part of the transaction, Jim Momtazee, KKR, will join Spirox’ Board of Directors.
The company intends to use the funds to scale the business.
Led by CEO Duke Rohlen, Spirox is developing a novel, minimally invasive system to be used by Ear, Nose and Throat (ENT) physicians and plastic surgeons to treat more than three million American patients with nasal obstruction who see a physician each year.